NDC product
ZELAPAR
NDC 0187-0453 · Bausch Health US, LLC
Key facts
| Product NDC | 0187-0453 |
|---|---|
| Proprietary name | ZELAPAR |
| Nonproprietary name | SELEGILINE HYDROCHLORIDE |
| Substances | SELEGILINE HYDROCHLORIDE |
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Route | ORAL |
| Labeler | Bausch Health US, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA021479 |
| Pharmacologic classes | Monoamine Oxidase Inhibitor [EPC], Monoamine Oxidase Inhibitors [MoA], Monoamine Oxidase Type B Inhibitor [EPC], Monoamine Oxidase-B Inhibitors [MoA] |
| Marketing start | Jun 14, 2006 |
| Marketing end | Jul 31, 2028 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory